ClinicalThought™
Interact with experts and peers.

Recent Posts

10 of 60 Shown
  • Ebola: Jumping on to the Front Lines

    Charles van der Horst MD - 11/18/2014
    How a transformative Skype call led me to leave for Liberia.
  • What the iPrEX Study Taught Me About Adherence Counseling

    Kevin M. O'Hara PA - 10/24/2014 1 comment / Last Comment: 11/7/2014
    iPrEX OLE showed that perfect adherence was not required to attain the benefits of PrEP. How should that influence our approach to adherence counseling for our patients?
  • A Quandary Over Switching: When Patients Resist My Recommendation to Switch

    David A. Wohl MD - 10/15/2014 3 comments / Last Comment: 11/26/2014
    I usually recommend patients who are still receiving lopinavir/ritonavir-based regimens to switch. But how strongly should I urge them to switch when they are reluctant?
  • Choosing a Single-Tablet Regimen for HIV Patients: What Do the Latest IAS-USA Guidelines Have to Say?

    Renslow Sherer MD - 10/7/2014 3 comments / Last Comment: 10/28/2014
    How I apply recent guidelines in daily practice to offer eligible patients the benefits of single-tablet regimens.
  • To Switch or Not to Switch: Management of First-line Boosted PI Virologic Failure

    W. David Hardy MD - 10/7/2014 2 comments / Last Comment: 11/18/2014
    After a first-line boosted PI regimen fails virologically, when is it OK to stay the course vs making a regimen switch?
  • Deintensification Strategies Using Boosted PIs: Are They Ready for Prime Time?

    Paul E. Sax MD - 10/7/2014 4 comments / Last Comment: 10/18/2014
    Recent studies have highlighted the potential efficacy of 2-drug boosted PI regimens. Are you considering integrating these strategies into your practice?
  • Sizing Up the Newest Integrase Inhibitor–Based Single-Tablet Regimen

    William G. Powderly MD - 9/22/2014 1 comment / Last Comment: 9/25/2014
    When it comes to ART, choice is good. And the recent FDA approval of the dolutegravir/abacavir/lamivudine single-tablet regimen contributes a very significant addition to our choices.
  • Should We Test for Integrase Inhibitor Resistance in Our Treatment-Naive Patients?

    Joseph J. Eron, Jr. MD - 9/22/2014 5 comments / Last Comment: 10/5/2014
    And if we do, how should we interpret and act upon the results? Here’s what I did in one of my patient cases.
  • Should Integrase Inhibitor Regimens Be Your First Choice When Starting HIV Therapy?

    Eric S. Daar MD - 8/25/2014
    Recently, one of my patients asked me why anyone would not choose to start therapy with one of the INSTI-based regimens. Here’s how I responded.
  • What 5257 Tells Us About the Selection of Integrase Inhibitor Regimens For HIV Therapy

    Joseph J. Eron, Jr. MD - 8/20/2014 2 comments / Last Comment: 10/4/2014
    Recent data may support the argument for selecting integrase inhibitors as first-line therapy for the majority of our patients. Get an idea of the key considerations I and my colleagues will discuss at an upcoming symposium addressing this question.
10 of 60 Shown
Show 10 More
Loading...